In HFrEF patients, reduced doses of sacubitril / valsartan do not result in increased mortality or heart failure hospitalizations compared to target dose. A retrospective cohort study
28 May 2018 (08:30 - 18:00)
Organised by:
Abstract
About the speaker
Hospital San Gennaro - ASL Napoli 1 Centre, Naples (Italy)
38 More presentations in this session
Access the full session
The Event
Heart Failure 2018
28 May 2018
08:30 CET
